Public Use Dataset

Login | Request access | Question

Public use datasets are available for the 6 clinical trials, Therapeutics for Inpatients with Covid-19 (TICO), conducted under the ACTIV-3 program;
Click on Request access and complete the contact information and you will receive a username and password that allows access to data from these 6 studies.

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigtational Therapeutics for Hospitalized Patients with COVID-19 (TICO)

The study will evaluate the safety and efficacy of multiple investigational agents intended to enhance the host immune response to SARS-CoV-2 infection, or directly enhance viral control, in order to limit disease progression. Using a master protocol, successive trials with the protocol will be adaptive, randomized, and initially placebo-controlled. All participants will receive standard of care (SOC) treatment. If an investigational agent shows superiority over placebo + SOC as initially defined, SOC for future investigational treatment evaluations will be modified accordingly. The initial investigational agents will be neutralizing monoclonal antibodies.
Protocol Summary

Major Results Publications for TICO Trials

A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 2021. ACTIV-3/TICO LY-CoV555 Study Group.
https://www.nejm.org/doi/10.1056/NEJMoa2033130

Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels. Ann Intern Med 2022. ACTIV-3/TICO Bamlanivimab Study Group
https://doi.org/10.7326/M21-3507

Efficacy and safety of two neutralizing monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalized with COVID-19 (TICO): a randomized controlled trial. ACTIV-3/TICO Study Group. Lancet Infect Dis 2021.
https://doi.org/10.1016/S1473-3099(21)00751-9

Tixagevimab-cilgavimab for treatment of patients hospitalized with COVID-19: a randomized, double-blind, phase 3 trial. Lancet Respir Med 2022. ACTIV-3/TICO Study Group.
https://doi.org/10.1016/S2213-2600(22)00215-6

Efficacy and safety of Ensovibep for adults hospitalized with COVID-19. Ann Intern Med 2022. ACTIV-3/TICO Study Group.
https://doi.org/10.7326/M22-1503